Spinocerebellar Ataxias (SCAs) are a group of rare, autosomal dominant diseases that result in progressive degeneration of the cerebellum. Of these, SCA1 is the fastest progressing. SCA3, the most prevalent SCA worldwide, is relentlessly progressive, disabling, and eventually fatal with no efficacious treatments other than supportive therapy. There is a strong need to improve our mechanistic understanding of the changes in the cerebello-cerebral circuitry prior to disease manifestation so that novel therapeutic strategies can be developed. Analyzing high quality magnetic resonance imaging data from the NIH-funded project, “Clinical Trial Readiness for SCA1 and SCA3 (READISCA),” will guide such efforts.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords